The global Antibody Drug Conjugates Market is expected to accrue lucrative revenue by 2023. Rising prevalence of cancer, rise in elderly population, advancement in medical technology, and strong pipeline drugs can propel the market over the forecast period (2018 to 2023). Antibody drug conjugates (ADC) are the new therapeutic agents that can target monoclonal antibodies as well as the cytotoxic drugs.
Development of targeted and combination therapies can create positive impact on the growth of the antibody drug conjugates market in the forthcoming years. Targeted therapies cause less side effects compared to conventional non-targeted therapies. This factor is anticipated to propel the product demand over the forecast period.
Targeting multiple pathways with ADC in conditions like cancer can reduce the risk of progression of treatment-resistant syndromes. Unhealthy and inactive lifestyle and growing consumption of tobacco and alcohol across the world are considered as the major factors causing cancer. Increasing demand for cost-effective and high quality cancer treatment can drive the market for antibody drug conjugates during the forecast period. ADCs are intended to eliminate cancer cells without hurting the normal cells. Hence ADCs can enable faster recovery.
However, high cost involved in the research and development (R&D) activities to discover new antibody drugs can impel the market growth. Apart from that, regulatory challenges and lack of established manufacturers can restrain the expansion of the market over the forecast period.
Access Sample Report of this report @ https://www.radiantinsights.com/research/global-antibody-drug-conjugates-drug-sales/request-sample
The worldwide antibody drug conjugates market can be segmented on the basis of product and regions. The report also analyzes the pipeline ADCs on the basis of clinical phase, indication, drug, type of linker, and technology. Based on commercially available products, the market can be categorized into Adcetris, Mylotarg, Kadcyla, and Besponsa. The report focuses on some of the major ADCs that are being developed by various companies and research institutes. Some of these antibody drug conjugates include Glembatumumab Vedotin Therapeutics/CDX-011 – Celldex, Polatuzumab Vedotin/RG7596 – F. Hoffman-La Roche Ltd., Coltuximab Ravtansine/SAR3419 – ImmunoGen Inc., and others.
Geographically, the antibody drug conjugates market can be divided into North America, Europe, and Asia Pacific. North America is expected to hold major market share over the forecast period. This dominance of the region can be attributed to availability of well-organized healthcare infrastructure, supportive government initiatives, and high healthcare budget for research and development activity. The United States is expected to be a major regional contributor due to increasing incidences of caners in the region. Asia Pacific, on the other hand, is likely to showcase rapid growth during the forecast period. This growth can be accredited to prevalence of cancer and high demand for cost-effective therapeutics to treat chronic diseases.
Prominent players operating in the antibody drug conjugates market include Celldex Therapeutics Inc.; Agensys, Inc.; Genentech USA, Inc.; F. Hoffmann-La Roche Ltd; Takeda Pharmaceuticals; and Seattle Genetics. The market highly competitive due to the presence of very few well-established companies. The entry of new manufacturers is expected increase the competition in terms of technological innovation, novel product development, and product extensions.
Complete Report Available @ https://www.radiantinsights.com/research/global-antibody-drug-conjugates-drug-sales
Additionally, the growing R&D activities for the discovery of antibody therapies, preclinical research, and oncology can create business opportunities for the market players. Growing alliances between research institutes and biotechnology and biopharmaceuticals firms are also expected to bode well for the global market.
For instance, Morphotek, Inc., recently introduced antibody drug conjugate based services. These services are based on the company’s patented eribulin-linker toxin platforms and REsidue-SPEcific Conjugation Technology (RESPECT). The platform allows site-specific conjugation of a single cytotoxic payload. It also allows two payloads with different mechanisms of action.
Explore Other Reports By Radiant Insights,Inc at
- Psoriatic Arthritis Treatment Market –
- Healthcare Supply Chain Outsourcing Market –
About Radiant Insight
Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: Send Email
Phone: (415) 349-0054, Toll Free: 1-888-928-9744
Address:201 Spear Street 1100, Suite 3036
City: San Francisco
Country: United States